<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35807537</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4292</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules27134292</ELocationID><Abstract><AbstractText>The main protease (M<sup>pro</sup>) of the betacoronavirus SARS-CoV-2 is an attractive target for the development of treatments for COVID-19. Structure-based design is a successful approach to discovering new inhibitors of the M<sup>pro</sup>. Starting from crystal structures of the M<sup>pro</sup> in complexes with the Hepatitis C virus NS3/4A protease inhibitors boceprevir and telaprevir, we optimized the potency of the alpha-ketoamide boceprevir against the M<sup>pro</sup> by replacing its P1 cyclobutyl moiety by a &#x3b3;-lactam as a glutamine surrogate. The resulting compound, <b>MG-78</b>, exhibited an IC<sub>50</sub> of 13 nM versus the recombinant M<sup>pro</sup>, and similar potency was observed for its P1' <i>N</i>-methyl derivative <b>MG-131</b>. Crystal structures confirmed the validity of our design concept. In addition to SARS-CoV-2 M<sup>pro</sup> inhibition, we also explored the activity of <b>MG-78</b> against the M<sup>pro</sup> of the alphacoronavirus HCoV NL63 and against enterovirus 3C proteases. The activities were good (0.33 &#xb5;M, HCoV-NL63 M<sup>pro</sup>), moderate (1.45 &#xb5;M, Coxsackievirus 3C<sup>pro</sup>), and relatively poor (6.7 &#xb5;M, enterovirus A71 3C<sup>pro</sup>), respectively. The structural basis for the differences in activities was revealed by X-ray crystallo-graphy. We conclude that the modified boceprevir scaffold is suitable for obtaining high-potency inhibitors of the coronavirus M<sup>pro</sup>s but further optimization would be needed to target enterovirus 3C<sup>pro</sup>s efficiently.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf6;hl</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology, Helmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of L&#xfc;beck, Ratzeburger Allee 160, 23562 L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Kilani</LastName><ForeName>Haifa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of L&#xfc;beck, Ratzeburger Allee 160, 23562 L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xinyuanyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of L&#xfc;beck, Ratzeburger Allee 160, 23562 L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kaixuan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of L&#xfc;beck, Ratzeburger Allee 160, 23562 L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xf6;nstrup</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8971-7045</Identifier><AffiliationInfo><Affiliation>Department of Chemical Biology, Helmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Hannover-Braunschweig Site, 38124 Braunschweig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilgenfeld</LastName><ForeName>Rolf</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8850-2977</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of L&#xfc;beck, Ratzeburger Allee 160, 23562 L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Hamburg-L&#xfc;beck-Borstel-Riems Site, 23562 L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>14-76103-184 Corona 13/20</GrantID><Agency>Ministry of Science and Culture of Lower Saxony, Germany</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>89BT58KELH</RegistryNumber><NameOfSubstance UI="C512204">N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C000706209">3C-like proteinase, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="N">Coronavirus 3C Proteases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3C-like protease</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">X-ray crystallography</Keyword><Keyword MajorTopicYN="N">alpha-ketoamides</Keyword><Keyword MajorTopicYN="N">boceprevir</Keyword><Keyword MajorTopicYN="N">enterovirus 3C protease</Keyword><Keyword MajorTopicYN="N">main protease</Keyword><Keyword MajorTopicYN="N">structure-based drug design</Keyword><Keyword MajorTopicYN="N">telaprevir</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35807537</ArticleId><ArticleId IdType="pmc">PMC9268446</ArticleId><ArticleId IdType="doi">10.3390/molecules27134292</ArticleId><ArticleId IdType="pii">molecules27134292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dai W., Zhang B., Jiang X.-M., Su H., Li J., Zhao Y., Xie X., Jin Z., Peng J., Liu F., et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331&#x2013;1335. doi: 10.1126/science.abb4489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4489</ArticleId><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaraz-Gir&#xf3;n M.A., Calder&#xf3;n-Jaimes E., Carrillo A.S., D&#xed;az-Cervantes E., Alonso E.C., Islas-J&#xe1;come A., Dom&#xed;nguez-Ortiz A., Casta&#xf1;&#xf3;n-Alonso S.L. Search for Non-Protein Protease Inhibitors Constituted with an Indole and Acetylene Core. Molecules. 2021;26:3817. doi: 10.3390/molecules26133817.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26133817</ArticleId><ArticleId IdType="pmc">PMC8270299</ArticleId><ArticleId IdType="pubmed">34201422</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289&#x2013;293. doi: 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Boras B., Jones R.M., Anson B.J., Arenson D., Aschenbrenner L., Bakowski M.A., Beutler N., Binder J., Chen E., Eng H., et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 2021;12:6055. doi: 10.1038/s41467-021-26239-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26239-2</ArticleId><ArticleId IdType="pmc">PMC8523698</ArticleId><ArticleId IdType="pubmed">34663813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidman D., Gehrtz P., Filep M., Fearon D., Gabizon R., Douangamath A., Prilusky J., Duberstein S., Cohen G., Owen C.D., et al. An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. Cell Chem. Biol. 2021;8:1795&#x2013;1806. doi: 10.1016/j.chembiol.2021.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2021.05.018</ArticleId><ArticleId IdType="pmc">PMC8228784</ArticleId><ArticleId IdType="pubmed">34174194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura N., Sacco M.D., Ma C., Hu Y., Townsend J.A., Meng X., Zhang F., Zhang X., Ba M., Szeto T., et al. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. J. Med. Chem. 2022;65:2848&#x2013;2865. doi: 10.1021/acs.jmedchem.1c00509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00509</ArticleId><ArticleId IdType="pmc">PMC8536799</ArticleId><ArticleId IdType="pubmed">33891389</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan B.-X., Shuai H., Xia A.-J., Hou Y., Zeng R., Liu X.-L., Lin G.-F., Qiao J.-X., Li W.-P., Wang F.-L., et al. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Nat. Microbiol. 2022;7:716&#x2013;725. doi: 10.1038/s41564-022-01119-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01119-7</ArticleId><ArticleId IdType="pubmed">35477751</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoh Y., Uehara S., Nakahara K., Nobori H., Yamatsu Y., Yamamoto S., Maruyama Y., Taoda Y., Kasamatsu K., Suto T., et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. J. Med. Chem. 2022;65:6499&#x2013;6512. doi: 10.1021/acs.jmedchem.2c00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00117</ArticleId><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Kusov Y., Nian Y., Ma Q., Wang J., von Brunn A., Leyssen P., Lanko K., Neyts J., et al. &#x3b1;-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment. J. Med. Chem. 2020;63:4562&#x2013;4578. doi: 10.1021/acs.jmedchem.9b01828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01828</ArticleId><ArticleId IdType="pubmed">32045235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x3b1;-ketoamide inhibitors. Science. 2020;368:409&#x2013;412. doi: 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Oerlemans R., Ruiz-Moreno A.J., Cong Y., Dinesh Kumar N., Velasco-Velazquez M.A., Neochoritis C.G., Smith J., Reggiori F., Groves M.R., Domling A. Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics. RSC Med. Chem. 2020;12:370&#x2013;379. doi: 10.1039/D0MD00367K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0MD00367K</ArticleId><ArticleId IdType="pmc">PMC8130630</ArticleId><ArticleId IdType="pubmed">34041486</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L., Ye F., Feng Y., Yu F., Wang Q., Wu W., Zhao C., Sun H., Huang B., Niu P., et al. Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 2020;11:4417. doi: 10.1038/s41467-020-18233-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18233-x</ArticleId><ArticleId IdType="pmc">PMC7474075</ArticleId><ArticleId IdType="pubmed">32887884</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao J., Li Y.S., Zeng R., Liu F.L., Luo R.H., Huang C., Wang Y.F., Zhang J., Quan B., Shen C., et al. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science. 2021;371:1374&#x2013;1378. doi: 10.1126/science.abf1611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf1611</ArticleId><ArticleId IdType="pmc">PMC8099175</ArticleId><ArticleId IdType="pubmed">33602867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneller D.W., Galanie S., Phillips G., O&#x2019;Neill H.M., Coates L., Kovalevsky A. Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals. Structure. 2020;28:1313&#x2013;1320. doi: 10.1016/j.str.2020.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2020.10.007</ArticleId><ArticleId IdType="pmc">PMC7584437</ArticleId><ArticleId IdType="pubmed">33152262</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera&#x2014;A visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605&#x2013;1612. doi: 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Prongay A.J., Guo Z., Yao N., Pichardo J., Fischmann T., Strickland C., Myers J., Weber P.C., Beyer B.M., Ingram R., et al. Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimenthyl-3-azabicyclo [3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization. J. Med. Chem. 2007;50:2310&#x2013;2318. doi: 10.1021/jm060173k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm060173k</ArticleId><ArticleId IdType="pubmed">17444623</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano K.P., Ali A., Aydin C., Soumana D., Ozen A., Deveau L.M., Silver C., Cao H., Newton A., Petropoulos C.J., et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8:e1002832. doi: 10.1371/journal.ppat.1002832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002832</ArticleId><ArticleId IdType="pmc">PMC3406087</ArticleId><ArticleId IdType="pubmed">22910833</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandl M., Weiss M.S., Jabs A., S&#xfc;hnel J., Hilgenfeld R. C-H&#xb7;&#xb7;&#xb7;&#x3c0;-interactions in proteins. J. Mol. Biol. 2001;307:357&#x2013;377. doi: 10.1006/jmbi.2000.4473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.2000.4473</ArticleId><ArticleId IdType="pubmed">11243825</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss M.S., Brandl M., S&#xfc;hnel J., Pal D., Hilgenfeld R. More hydrogen bonds for the (structural) biologist. Trends Biochem. Sci. 2001;26:521&#x2013;523. doi: 10.1016/S0968-0004(01)01935-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0004(01)01935-1</ArticleId><ArticleId IdType="pubmed">11551776</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science. 2003;300:1763&#x2013;1767. doi: 10.1126/science.1085658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1085658</ArticleId><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., Zhao Q., Zhou Z., Pei D., Ziebuhr J., et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3:e324. doi: 10.1371/journal.pbio.0030428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0030428</ArticleId><ArticleId IdType="pmc">PMC1197287</ArticleId><ArticleId IdType="pubmed">16128623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalerao D.S., Arkala A.K.R., Madhavi Y.V., Nagaraju M., Gade S.R., Kumar U.K.S., Bandichhor R., Dahanukar V.H. Synthesis and Process Optimization of Boceprevir: A Protease Inhibitor Drug. Org. Process Res. Dev. 2015;19:1559&#x2013;1567. doi: 10.1021/op500065t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/op500065t</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschueren K.H., Pumpor K., Anem&#xfc;ller S., Chen S., Mesters J.R., Hilgenfeld R. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem. Biol. 2008;15:597&#x2013;606. doi: 10.1016/j.chembiol.2008.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2008.04.011</ArticleId><ArticleId IdType="pmc">PMC7110992</ArticleId><ArticleId IdType="pubmed">18559270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rut W., Groborz K., Zhang L., Sun X., Zmudzinski M., Pawlik B., Wang X., Jochmans D., Neyts J., M&#x142;ynarski W., et al. SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. 2021;17:222&#x2013;228. doi: 10.1038/s41589-020-00689-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-020-00689-z</ArticleId><ArticleId IdType="pubmed">33093684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney T.R., Roqu&#xe9;-Rosell N., Birtley J.R., Leatherbarrow R.J., Curry S. Structural and Mutagenic Analysis of Foot-and-Mouth Disease Virus 3C Protease Reveals the Role of the &#x3b2;-Ribbon in Proteolysis. J. Virol. 2007;81:115&#x2013;124. doi: 10.1128/JVI.01587-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01587-06</ArticleId><ArticleId IdType="pmc">PMC1797255</ArticleId><ArticleId IdType="pubmed">17065215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Beyer B.M., Durkin J., Ingram R., Njoroge F.G., Windsor W.T., Malcolm B.A. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 1999;270:268&#x2013;275. doi: 10.1006/abio.1999.4109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/abio.1999.4109</ArticleId><ArticleId IdType="pubmed">10334844</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison J.F., Walsh C.T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat Areas Mol. Biol. 1988;61:201&#x2013;301. doi: 10.1002/9780470123072.ch5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470123072.ch5</ArticleId><ArticleId IdType="pubmed">3281418</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Z., Sacco M., Hu Y., Ma C., Meng X., Zhang F., Szeto T., Xiang Y., Chen Y., Wang J. Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir. ACS Pharmacol. Transl. Sci. 2021;4:1408&#x2013;1421. doi: 10.1021/acsptsci.1c00099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.1c00099</ArticleId><ArticleId IdType="pmc">PMC8204911</ArticleId><ArticleId IdType="pubmed">34414360</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Zhou R., Skalitzky D.J., Fuhrman S.A., Patick A.K., Ford C.E., Meador J.W., 3rd, Worland S.T. Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. Bioorg. Med. Chem. 1999;7:589&#x2013;598. doi: 10.1016/S0968-0896(99)00005-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0896(99)00005-X</ArticleId><ArticleId IdType="pubmed">10353638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., George S., Kusov Y., Perbandt M., Anem&#xfc;ller S., Mesters J.R., Norder H., Coutard B., Lacroix C., Leyssen P., et al. 3C protease of enterovirus 68: Structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J. Virol. 2013;87:4339&#x2013;4351. doi: 10.1128/JVI.01123-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01123-12</ArticleId><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., George S., Schmidt M.F., Al-Gharabli S.I., Rademann J., Hilgenfeld R. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antivir. Res. 2011;92:204&#x2013;212. doi: 10.1016/j.antiviral.2011.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.08.001</ArticleId><ArticleId IdType="pmc">PMC7114241</ArticleId><ArticleId IdType="pubmed">21854807</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586&#x2013;1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K., Palm G.J., Mesters J.R., Siddell S.G., Ziebuhr J., Hilgenfeld R. Structure of coronavirus main protease reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002;21:3213&#x2013;3224. doi: 10.1093/emboj/cdf327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdf327</ArticleId><ArticleId IdType="pmc">PMC126080</ArticleId><ArticleId IdType="pubmed">12093723</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Song J. The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain. FEBS J. 2006;273:1035&#x2013;1045. doi: 10.1111/j.1742-4658.2006.05130.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2006.05130.x</ArticleId><ArticleId IdType="pmc">PMC7164011</ArticleId><ArticleId IdType="pubmed">16478476</ArticleId></ArticleIdList></Reference><Reference><Citation>Norder H., De Palma A.M., Selisko B., Costenaro L., Papageorgiou N., Arnan C., Coutard B., Lantez V., De Lamballerie X., Baronti C., et al. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antivir. Res. 2011;89:204&#x2013;218. doi: 10.1016/j.antiviral.2010.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2010.12.007</ArticleId><ArticleId IdType="pubmed">21236302</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug M., Weiss M.S., Heinemann U., Mueller U. XDSAPP: A graphical user interface for the convenient processing of diffraction data using XDS. J. Appl. Crystallogr. 2012;45:568&#x2013;572. doi: 10.1107/S0021889812011715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0021889812011715</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 2006;62:72&#x2013;82. doi: 10.1107/S0907444905036693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444905036693</ArticleId><ArticleId IdType="pubmed">16369096</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans P.R. An introduction to data reduction: Space-group determination, scaling and intensity statistics. Acta Crystallogr. D Biol. Crystallogr. 2011;67:282&#x2013;292. doi: 10.1107/S090744491003982X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S090744491003982X</ArticleId><ArticleId IdType="pmc">PMC3069743</ArticleId><ArticleId IdType="pubmed">21460446</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn M.D., Ballard C.C., Cowtan K.D., Dodson E.J., Emsley P., Evans P.R., Keegan R.M., Krissinel E.B., Leslie A.G.W., McCoy A., et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 2011;67:235&#x2013;242. doi: 10.1107/S0907444910045749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910045749</ArticleId><ArticleId IdType="pmc">PMC3069738</ArticleId><ArticleId IdType="pubmed">21460441</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagin A., Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 2010;66:22&#x2013;25. doi: 10.1107/S0907444909042589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042589</ArticleId><ArticleId IdType="pubmed">20057045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebedev A.A., Young P., Isupov M.N., Moroz O.V., Vagin A.A., Murshudov G.N. JLigand: A graphical tool for the CCP4 template-restraint library. Acta Crystallogr. D Biol. Crystallogr. 2012;68:431&#x2013;440. doi: 10.1107/S090744491200251X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S090744491200251X</ArticleId><ArticleId IdType="pmc">PMC3322602</ArticleId><ArticleId IdType="pubmed">22505263</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010;66:486&#x2013;501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov G.N., Skub&#xe1;k P., Lebedev A.A., Pannu N.S., Steiner R.A., Nicholls R.A., Winn M.D., Long F., Vagin A.A. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 2011;67:355&#x2013;367. doi: 10.1107/S0907444911001314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444911001314</ArticleId><ArticleId IdType="pmc">PMC3069751</ArticleId><ArticleId IdType="pubmed">21460454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>